title: [Successful treatment with rituximab in a patient with primary thymic MALT lymphoma complicated with acquired von Willebrand syndrome and Sjögren syndrome].
abstract: A 53-year-old female developed epigastric discomfort and back pain in 2007. Diagnostic imaging studies demonstrated a soft tissue tumor with heterogeneous enhancement in the anterior mediastinum and multiple nodules in the right lung. She underwent expanded thymectomy with subtotal resection of the right lung. The pathological diagnosis was primary thymic mucosa-associated lymphoid tissue (MALT) lymphoma. The patient complained of ocular discomfort, oral dryness and continuous nasal bleeding in 2007. Detailed examination led to a diagnosis of Sjögren syndrome and acquired von Willebrand syndrome. Rituximab treatment for residual disease achieved not only a reduction of the lung MALT lymphoma but also clinical and hematological remission of both syndromes. This is, to our knowledge, the first reported case of primary thymic MALT lymphoma accompanied by Sjögren and acquired von Willebrand syndromes.
authors.affiliation: Department of First Internal Medicine, Tokyo Medical University Hospital Division of Hematology, Tokyo Medical University Hospital.
authors.forename: Tamiko
authors.initials: T
authors.lastname: Iwabuchi
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Kimura
authors.forename: Takashi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Haeru
authors.initials: H
authors.lastname: Hayashi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Fujimoto
authors.forename: Yuko
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kusama
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Fukutake
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ohyashiki
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000628:therapy; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications* / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D008875:Middle Aged; D011013:Pneumonectomy; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications* / Q000628:therapy; D013934:Thymectomy; D013953:Thymus Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000150:complications* / Q000628:therapy
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab